Product Details
1/EA
$1,390.95
In StockAdditional Information
| Product Name | Ruxience 100 mg/10 mL Vial |
| Generic Name | Rituximab-pvvr |
| Drug Class | Monoclonal Antibody, CD20 Inhibitor |
| Mechanism of Action | Binds to CD20 on B-cells, inducing cell death |
| Strength | 100 mg/10 mL (10 mg/mL) |
| Dosage Form | Injectable Solution |
| Common Side Effects | Infusion reactions, fever, chills, nausea, fatigue |
| Serious Adverse Effects | Progressive multifocal leukoencephalopathy (PML), severe mucocutaneous reactions, fatal infusion reactions |
| Precautions | Monitor for infection, tumor lysis syndrome, infusion reactions |
| Preparation & Handling | Dilute with 0.9% sodium chloride or 5% dextrose under aseptic conditions |
| Packaging | Single-use glass vial |
| Storage Conditions | 2°C to 8°C (Refrigerated); protect from light; do not freeze or shake |
| Uses | Non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) |
Description
Ruxience (rituximab-pvvr) is a biosimilar to Rituxan, classified as a monoclonal antibody targeting CD20-expressing B-cells. It binds to the CD20 antigen on the surface of malignant and normal B lymphocytes, inducing cell death through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis. It is indicated for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA).
Each 10 mL vial contains 100 mg of rituximab-pvvr in a preservative-free solution. The formulation includes polysorbate 80, sodium citrate, and sodium chloride to maintain stability and solubility. The solution should be stored at 2°C to 8°C and protected from light. It must not be frozen or shaken. Dilution should be performed under aseptic conditions using sterile 0.9% sodium chloride or 5% dextrose before intravenous infusion.
Common adverse reactions include infusion-related reactions, fever, chills, nausea, and fatigue. Severe risks involve progressive multifocal leukoencephalopathy (PML), severe mucocutaneous reactions, and fatal infusion reactions. Patients should be monitored for signs of infection, hypersensitivity, and tumor lysis syndrome.
Frequently Asked Questions (FAQs)
The cost of RUXIENCE 100 MG/10 ML VIAL is $$1,390.95
RUXIENCE 100 MG/10 ML VIAL is manufactured by Pfizer.
You can purchase RUXIENCE 100 MG/10 ML VIAL on our website at https://supplies.pipelinemedical.com/product/detail/ruxience-sf-10mg-ml-10ml-651322